

ICN PHARMACEUTICALS INC
Form 8-K
May 05, 2003

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of the Earliest Event Reported: May 5, 2003

Date of Report: May 5, 2003

ICN Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

1-11397
(Commission
file number)

33-0628076
(I.R.S. Employer
Identification No.)

Edgar Filing: ICN PHARMACEUTICALS INC - Form 8-K

3300 Hyland Avenue

Costa Mesa, California 92626

(Address of principal executive offices) (Zip code)

(714) 545-0100

(Registrant's telephone

number, including area code)

Item 7. Financial Statements and Exhibits.

(c) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated May 5, 2003

Item 9. Regulation FD Disclosure.

The following information is furnished pursuant to Item 12, Disclosure of Results of Operations and Financial Conditions.

On May 5, 2003, ICN Pharmaceuticals, Inc. issued a press release announcing its first fiscal quarter results ended March 31, 2003 and will hold a conference call on such date. The press release is attached as Exhibit 99.1.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, ICN Pharmaceuticals, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 5, 2003

ICN PHARMACEUTICALS, INC.

/s/ Robert W. O Leary

Chairman and Chief Executive Officer